

Article

Not peer-reviewed version

Fractional Exhaled Nitric Oxide (FeNO) in Biomass Smoke-associated Chronic Obstructive Pulmonary Disease

[Juan Silva-Gallardo](#) , Raúl H. Sansores , Alejandra Ramírez-Venegas , [Robinson Robles-Hernández](#) ,
[Gustavo I. Centeno-Saenz](#) , [Rafael J. Hernández-Zenteno](#) *

Posted Date: 28 August 2024

doi: 10.20944/preprints202408.2011.v1

Keywords: Biomass COPD; FeNO; Inflammation



Preprints.org is a free multidiscipline platform providing preprint service that is dedicated to making early versions of research outputs permanently available and citable. Preprints posted at Preprints.org appear in Web of Science, Crossref, Google Scholar, Scilit, Europe PMC.

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Disclaimer/Publisher's Note: The statements, opinions, and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions, or products referred to in the content.

Article

Fractional Exhaled Nitric Oxide (FeNO) in Biomass Smoke-associated Chronic Obstructive Pulmonary Disease

Juan Silva-Gallardo ¹, Raúl H. Sansores ², Alejandra Ramírez-Venegas ³, Robinson Robles Hernández ³, Gustavo I. Centeno-Saenz ³ and Rafael J. Hernández-Zenteno ^{4,*}

¹ Hospital General Regional 25 / Instituto Mexicano del Seguro Social, Mexico City, Mexico; mely0306@yahoo.com.mx

² Respiratory Department / Hospital Médica Sur, Mexico City, Mexico; raulsansores@yahoo.com.mx

³ Tobacco and COPD Research Department / Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico City, Mexico; aleraves@gmail.com (A.R.R.); robinsonrobher@gmail.com (R.R.H.); igcenteno89@gmail.com (G.I.C.S.)

⁴ COPD and Bronchiectasis Clinic / Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico City, Mexico; rafherzen@gmail.com

* Correspondence: rafherzen@gmail.com ; Tel.: +52-55-1343-7480

Abstract: Chronic Obstructive Pulmonary Disease (COPD) is a disease characterized by local and systemic inflammation independently of the risk factor; during the exacerbations, such inflammation is accentuated and amplified. A practical inflammatory marker and one with an applicable predictive value in the follow-up has been sought. FeNO has shown an excellent performance in that respect within the context of asthma and has also been studied in tobacco-smoke COPD (COPD-TS). In Biomass-smoke COPD (COPD-BS), this, to our knowledge, has not been evaluated. **Objective:** To measure FeNO levels in patients with COPD-BS and to compare these with those of patients with stable COPD-TS and in healthy controls. **Methods:** Transversal, observational, descriptive, comparative, and analytical study. A total of 57 patients, including 23 with COPD-BS, 17 with COPD-TS, and 17 healthy control subjects. The measurement of FeNO was carried out on all of these by means of the on-line chemiluminescence technique; the values were expressed in parts per billion (ppb) for their analysis. **Results:** It was observed that the FeNO values were similar between COPD-BS and COPD-TS and were significantly different between the healthy and stable COPD (both groups). No correlation was found between pulmonary function and symptoms with FeNO in any of the groups. **Conclusions:** The level of FeNO in stable COPD is found to be increased in a similar manner in COPD-BS and COPD-TS, with a significant difference on comparing it with that of the healthy subjects.

Keywords: biomass COPD; FeNO; inflammation

1. Introduction

Chronic Obstructive Pulmonary Disease (COPD) is an inflammatory disease characterized by the partially reversible obstruction of the air flow; it is generally accompanied by mucous hypersecretion and oxidative stress in the airways and in the lungs [1]. The principal cause of COPD at the worldwide level is tobacco smoking (TS); however, in developing countries, another risk factor comprises chronic exposure to biomass (wood) smoke (BS), which presents above all in women who employ this energy source to cook and to heat their homes [2]. Although both types of COPD share physiological changes, important functional and clinical differences have been described [3,4]. Fractional exhaled Nitric Oxide (FeNO) is one of the inflammatory biomarkers that is synthesized in the airways, and it plays a key role in physiological regulation, acting as neurotransmitter, vasodilator, and in immunoregulation [5]. The increase of FeNO has been widely described and

studied in inflammatory disease of the airways mainly in asthma, cystic fibrosis, and pulmonary hypertension [6]. Measuring FeNO in the exhaled air in inflammatory diseases of the airways has become an attractive auxiliary tool in the detection and follow-up of these diseases because it is a simple, non-invasive method that has demonstrated clinical utility and that has been standardized and recommended by the American Thoracic Society (ATS) for the study and follow-up of patients with asthma, in children and adults [7]. However, its usefulness in COPD continues to be controversial; although there are works that have investigated diverse profiles of FeNO, in COPD the results have been disappointing and inconsistent, giving rise to confusion [8]; there are, to our knowledge, no studies that have evaluated the behavior of this biomarker in COPD-BS. One might think that, due to that the phenotype of COPD-BS is due more to the airway and not to emphysema, these levels could be found more elevated in these patients on comparison with those of COPD-TS.

To explore this association, we decided to carry out this study in a sample of patients previously diagnosed with COPD-BS in a cohort of patients at the Mexican National Institute of Respiratory Diseases (INER) seen at the Institute's Outpatient Service, and we compared the results with those of patients with COPD-TS, both groups in stable condition. The study also included a control group of healthy adults aged over 40 years in order to contrast the results and to observe their differences.

2. Materials and Methods

2.1. Study Population

The study was carried out in Mexico City in the National Institute of Respiratory Diseases (INER) at the COPD Clinic Patient Consultation Service. We recruited three groups of patients (COPD-BS, COPD-TS, and healthy subjects who had received a FeNO measurement). The healthy subjects were recruited from among the volunteer hospital personnel or from among the relatives of the patients with sociodemographic characteristics similar to those of the patients with COPD.

A brief questionnaire was applied to all of these control subjects in order to ensure that they were healthy, without antecedents of tobacco smoking in the past nor at present nor any other type of addiction, and who did not have any type of respiratory disease, nor atopies, nor chronic rhinosinusitis.

All of these individuals were invited to participate by means of a telephone call. On a capture sheet we obtained their general data, clinical state, the data from their last spirometry, the etiology of the COPD (tobacco smoking or wood smoke), the state of the smoker, with their index of smoking and/or exposure to wood smoke, the severity of the stable disease according to standard "GOLD" criteria, the use of inhaled or systemic steroids, the presence of comorbid processes, and the degree of dyspnea based on the scale of the modified Medical Research Council (mMRC). All of the patients signed the informed consent document in order to participate in the study, which was reviewed and approved by both the local ethics review boards and the Institutional Review Board (Protocol C08-05) in accordance with the principles of the Declaration of Helsinki. The tests were performed during the morning hospital shift by the principal researcher (SGJ).

The values of FeNO were captured in a database and were expressed in parts per billion (ppb) for their analysis.

2.2. Measurement Technique of Nitric Oxide

We employed the on-line chemiluminescence measurement technique after a prior review of the Users' Manual of the brand of the equipment utilized (NO Analyzer-Sievers™, version 3.2 software) (CO, USA). We conducted a daily calibration of the equipment prior to carrying out the test according to the manufacturer's recommendations.

We followed the recommendations for the ATS and European Respiratory Society (ERS) tests in adults [9]. We utilized the XP operative system. This method employs a constant flow velocity of 50 \pm 5 ml/s. The measurements were always performed prior to 10 a.m., asking the patient to exhale the air from their total lung capacity, and the patient received an indication at the moment of carrying out the test to observe a chromatic bar indicator displaying flow and pressure on the computer screen.

The objective of this was to maintain the expiratory flow for the longest time possible (at least 6 s) and to be able to reach a plateau of 3 s. In addition, to avoid leaks, the patients were asked to maintain a hermetic seal between their lips and the specific mouthpiece filter; with the latter, a pressure level in the mouth is generated of between 5 and 20 cm H₂O, which allows for the closure of the veli palatini, thus avoiding contamination with nasal gas.

All of the subjects had at least three acceptable measurements at intervals of at least 3 s between each measurement. The values measured were considered acceptable if the variability between these measurements was less than 5%. The average value of the two highest measurements was considered as the final FeNO (Figure 1).

2.3. Statistical Analyses

Parametric tests were employed to describe the general population of the patients using means and standard deviations (SD). Comparison of the demographic variables among the three groups of study participants was carried out by the analysis of repeated samples (Analysis of Variance, ANOVA). Due to that the measurement of FeNO did not maintain a normal distribution, we utilized a non-parametric analysis for repeated samples (Kruskal-Wallis). To determine where the differences were found, we performed non-paired analyses utilizing the un-paired Student t test or the Mann-Whitney U test according to the distribution of the data. To ascertain whether there existed some correlation between FeNO and the degree of obstruction and the measurement of dyspnea, we utilized the Pearson r correlation test.

3. Results

In Table 1, we find the demographic data of the patients included in the study. Significant differences were observed of the Forced Expiration Value (FEV)1 ($p < 0.03$) between the two groups of patients with COPD. Around 50% of the patients were classified as GOLD IV. The treatments with bronchodilators and steroids were similar for both groups. In the two groups, around 60% were utilizing inhaled steroids. The results of the FeNO measurements of the two COPD groups and of the healthy control group are presented in Figure 1, in which it is observed that there were only statistically significant differences among the healthy subjects and the two COPD groups ($p = 0.001$), but not between the COPD groups ($p < 0.2$).

There was no correlation between pulmonary function and dyspnea with the levels of FeNO for any of the groups.




Figure 1. Comparison of FeNO in stable patients Vs Healthy.

Table 1. Comparison between the two stable groups: COPD-BS vs. COPD-TS vs. the healthy controls group.

Variables	COPD-BS n = 23	COPD-TS n = 17	HEALTHY n=17	P value
Demographic data				
M/F Gender (% M)	1/22 (4,3)	13/4 (76,5)	3/14 (17,6)	< 0,0001
Age (years)	74,0±7,18	73,5±8,2	52,4±12,3	< 0,0001
Risk factors				
Smoking n (%)	--	2/17 (11,8)	--	< 0,0001
Currently Ex-smoker	--	15/17 (88,2)	2/17 (11,8)	
Never-smoker	23/23(100,0)	--	15/17 (88,2)	
Smoking index (packs per year)	--	44,05±24,0	--	--
Wood exposure index (years)	291,68±139,39	--	--	--
Pulmonary function data				
GOLD n (%)				
0-II	9/23 (21,7)	6/17 (11.7)	--	0,542
III-IV	14/23 (4,3)	11/17 (11,7)	--	
Dyspnea mMRC n%				0,017
0 – 1	6/22 (27.3)	8/17(47.1)		
2 - 4	16/22 (72.7)	9/17(52.9)		
FEV1, L	1,14±0,34	1,35±0,51	--	0,16
FEV1% predicted	70,80±20,64	54,81±23,08	--	0,035
FVC % predicted	85,00±15,94	78,5±25,51	--	0,356
FVC/FEV1 %	64,90±12,77	52,00±13,08	--	0,005
Steroid use Yes/No				
(%Yes)	15/6 (65,2)	10/5 (59.0)	--	0,521
FeNO (ppb) median (range IC)	9.40 (4.8 – 28.2)	12.6 (7.5-34.9)	4.8 (2.5-14.1)	<0,0001

Proportions n%, mean ± standard deviation (SD) or median with interquartile (IQ) ranges according to the variable.

4. Discussion

This is, to our knowledge, the first study that measures the values of the nitric-oxide levels (NO) in COPD-BS and that compares these with those of COPD-TS. This study demonstrates that the levels of FeNO in patients with COPD-BS are similar to those in patients with COPD-TS found in stable condition, suggesting that they share the same physiopathological processes of inflammation and oxidative stress.

An overlap was observed of the levels of FeNO between the healthy control-group subjects and the two groups of stable COPD, as has been reported in a meta-analysis that evaluated FeNO in patients with stable COPD who were also compared with healthy controls [5]. In this systemic review and meta-analysis, the authors describe only from 1998-2017; in 18 studies, the measurement was conducted with the chemiluminescence technique, while in 13 studies, FeNO levels were higher than those in the healthy control group, while in the remainder of the studies [11], there was no difference.

We did not find an association between pulmonary function and the FeNO level, as reported by Beg and Fan et al. [8,10], and only observed a correlation between COPD in relation to Forced Expiration Volume at 1 s (FEV1)/Forced Vital Capacity (FVC). We also did not find a correlation between FeNO levels, and the disease severity of COPD based on the degree of obstruction [10].

We did not include patients with exacerbated COPD. Few studies have evaluated FeNO in stable condition, where attention is drawn to that in a stable condition, the FeNO level was even higher than in exacerbated patients (41 vs. 13 ppb) [5]. Another interesting observation lies in that ex-smokers express a lesser concentration of FeNO (2 ppb less) than active smokers, because tobacco smoke

inhibits the inducible isoform of nitric oxide synthase; in our population, the majority of the patients were no longer exposed to tobacco nor to the biomass [5].

The patients with COPD-BS had a FeNO level similar to that of patients with COPD-TS; these findings suggest that, despite that the COPD-BS phenotype is predominantly through the airway, it could not be a biomarker to distinguish the most accentuated damage of the airway in this phenotype.

Although the standardized FeNO measurement technique by ATS/ERS was that of on-line chemiluminescence in 2005, in recent years novel portable devices with different technologies have been validated by the U.S. Food and Drug Administration (FDA), due to their high correlation with the standardized technique considered the “GOLD” standard, which is chemiluminescence, reporting an excellent correlation in persons with asthma and in healthy subjects ($r = 0.94$ and 0.96 , respectively) [11], in that the equipment for chemiluminescence is desk-oriented and utilizes a computer, rendering it of easy, at-hand access for this measurement. This draws our attention to that our values measured with FeNO are in general lower than the measurements in the majority of studies conducted on this subject matter, which we attribute probably to three possible reasons. The majority of patients with COPD-BS were women who were on average short in height, which is a factor that modifies the level of FeNO [12]. When the value of FeNO has been compared between men and women, it is lower in women (16.8 vs. 14.3 ppb, a difference of 2.5 ppb) [13]; it could be that the lungs of the shortest women exhibit a lower surface expression of NO. On the other hand, around one half of the patients in both groups used inhaled steroids in their treatment, the reason for which, on their having an anti-inflammatory treatment, the latter could exert an influence on the levels of FeNO, as has been observed in asthma. The study of Fan et al. [10], which evaluated hospitalized exacerbated patients with asthma, demonstrated that after a course of systemic steroids, there is a slight but significant diminution of FeNO. However, the employment of inhaled steroids has not, to our knowledge, been evaluated in patients with COPD. Finally, the measurements were performed at an average altitude of 2,250 meters above sea level (masl). It is known that altitude entertains an inverse correlation with FeNO, as reported by Ren et al. [13], who demonstrated, in healthy adult subjects in some studies in Tibet, a mean of 15.4 ppb.

One of the limitations of this study was not having performed spirometries in the healthy subjects, in whom we had objectively discarded the presence of obstruction or functional restriction. Another limitation of our study is that we did not conduct measurements of eosinophils in blood or in sputum, and of immunoglobulin E, which could have aided in investigating possible atopies in some patients.

Another of the limitations of our study was that the measurement of FeNO was unique for each study participant; however, it has been demonstrated that the individual variability of this test did not exhibit significant differences (3.9 ppb) when measured at different moments in the short term [14].

On the other hand, the sample size of the patients studied is small; thus, it could not be representative of the findings reported.

5. Conclusions

We are able to conclude that the levels of FeNO in patients with stable COPD-BS are similar to the values reported in COPD-TS. More studies should be conducted in order to elucidate the role of FeNO in COPD-BS.

Author Contributions: Conceptualization, Juan Silva-Gallardo, Raúl Sansores and Rafael Hernández-Zenteno; Data curation, Gustavo Centeno-Saenz; Formal analysis, Robinson Robles-Hernández and Gustavo Centeno-Saenz; Funding acquisition, Alejandra Ramírez-Venegas; Investigation, Juan Silva-Gallardo; Methodology, Alejandra Ramírez-Venegas and Rafael Hernández-Zenteno; Project administration, Rafael Hernández-Zenteno; Supervision, Rafael Hernández-Zenteno; Visualization, Robinson Robles-Hernández; Writing – original draft, Juan Silva-Gallardo; Writing – review & editing, Raúl Sansores and Alejandra Ramírez-Venegas. All authors have read and agreed to the published version of the manuscript.” Please turn to the CRediT taxonomy for the term explanation. Authorship must be limited to those who have contributed substantially to the work reported.

Funding: This research received no external funding.

Institutional Review Board Statement: Approved by both the local ethics review boards and the Institutional Review Board (Protocol C08-05) in accordance with the principles of the Declaration of Helsinki

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: The datasets used and/or analyzed during the current study are available from the corresponding author upon reasonable request.

Acknowledgments: We are grateful to the National Institute of Respiratory Diseases of Mexico and the Chamber of Deputies of Mexico for establishing a program to treat COPD due to wood smoke.

Conflicts of Interest: "The authors declare no conflicts of interest related with the present work."

References

1. Agustí A, Celli BR, Criner GJ, et al. Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary. *Eur Respir J.* 2023;61(4):2300239. Published 2023 Apr 1. doi:10.1183/13993003.00239-2023
2. Pérez-Padilla R, Regalado J, Vedral S, et al. Exposure to biomass smoke and chronic airway disease in Mexican women. A case-control study. *Am J Respir Crit Care Med.* 1996;154(3 Pt 1):701-706. doi:10.1164/ajrccm.154.3.8810608
3. Ramírez-Venegas A, Sansores RH, Pérez-Padilla R, et al. Survival of patients with chronic obstructive pulmonary disease due to biomass smoke and tobacco. *Am J Respir Crit Care Med.* 2006;173(4):393-397. doi:10.1164/rccm.200504-568OC
4. Aghaeimeybodi F, Samadzadeh G, Haji Safari Z, Nouri S, Talebi HR, Shahcheraghi SH. Comparison of Chronic Obstructive Pulmonary Diseases Induced by Wood Smoke and Tobacco Smoke. *Tanaffos.* 2021;20(3):268-276.
5. Lu Z, Huang W, Wang L, Xu N, Ding Q, Cao C. Exhaled nitric oxide in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. *Int J Chron Obstruct Pulmon Dis.* 2018;13:2695-2705. Published 2018 Aug 30. doi:10.2147/COPD.S165780
6. Malinovschi A, Ludviksdottir D, Tufvesson E, et al. Application of nitric oxide measurements in clinical conditions beyond asthma. *Eur Clin Respir J.* 2015;2:28517. Published 2015 Aug 17. doi:10.3402/ecrj.v2.28517
7. Dweik RA, Boggs PB, Erzurum SC, et al. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. *Am J Respir Crit Care Med.* 2011;184(5):602-615. doi:10.1164/rccm.9120-11ST
8. Beg MF, Alzoghaibi MA, Abba AA, Habib SS. Exhaled nitric oxide in stable chronic obstructive pulmonary disease. *Ann Thorac Med.* 2009;4(2):65-70. doi:10.4103/1817-1737.44649
9. Kharitonov S, Alving K, Barnes PJ. Exhaled and nasal nitric oxide measurements: recommendations. The European Respiratory Society Task Force. *Eur Respir J.* 1997;10(7):1683-1693. doi:10.1183/09031936.97.10071683
10. Fan X, Zhao N, Yu Z, et al. Clinical Utility of Central and Peripheral Airway Nitric Oxide in Aging Patients with Stable and Acute Exacerbated Chronic Obstructive Pulmonary Disease. *Int J Gen Med.* 2021;14:571-580. Published 2021 Feb 23. doi:10.2147/IJGM.S284688
11. Menzies D, Nair A, Lipworth BJ. Portable exhaled nitric oxide measurement: comparison with the "gold standard" technique. *Chest.* 2007;131(2):410-414. doi:10.1378/chest.06-1335
12. Dweik RA, Boggs PB, Erzurum SC, et al. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. *Am J Respir Crit Care Med.* 2011;184(5):602-615. doi:10.1164/rccm.9120-11ST
13. Ren X, Wang H, Hong H, et al. Fractional exhaled nitric oxide in healthy Tibetans at high altitude. *Med Sci Monit.* 2014;20:2565-2570. Published 2014 Dec 7. doi:10.12659/MSM.891369
14. Ambrosino, P, Fuschillo S, Accardo M, Mosella M, Molino A, Spedicato GA, Motta, A, Maniscalco M. Fractional Exhaled Nitric Oxide (FeNO) in Patients with Stable Chronic Obstructive Pulmonary Disease: Short-Term Variability and Potential Clinical Implications. *J. Pers. Med.* 2022;12:1906.

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.